This increases the range and flexibility of biochemical investigation of triggers (e.g. preparations from AD tissue or transgenic animals) and responses (e.g. abnormal changes in Tau, dependence on mutations), but makes the interpretation in terms of PHF aggregation less specific. Here, MAPT is linked to Alzheimer disease.